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Swedish Cystic Fibrosis (CF) care follows international guidelines in general. The only differ-
ence in our CF care package since 25 years is the physiotherapy regimen. Airway clearance
therapy has since the early 1980s, from the day of diagnosis, been based upon daily physical
exercise in conjunction with techniques for transporting and evacuating mucus. Postural Drai-
nage percussion and vibration has not been used in any age. The aim of this study was to
evaluate our CF care package.
Lung function data from the start of the study and with a 3-year interval were collected in
the entire Swedish CF population 7 years old. Data were analysed for the age groups 7e17
and 18 years of age. Change of lung function over the study period was calculated. The
impact of chronic Pseudomonas aeruginosa (Pa) colonisation and basal FEV1%p was also eval-
uated in a linear mixed model.
Data from 99% of the country-wide CF population were available at inclusion. Mean FEV1%p
was 90 21 vs 73 26 in the different age groups and mean VC%p was 94 18 vs 91 20. Fortys in Sweden, summarised, analysed and authorized at Department of Respiratory Medicine, Lund
6177756; fax: þ46 46173959.
skane.se (U. Dennersten).
9 Published by Elsevier Ltd.
Aging cystic fibrosis patients and lung function 1077percent of the adult group was 30 years old. Overall, 41% were chronically Pa colonised. Mean
annual FEV1%p rate of decline was 0.77 and 0.64 in the different age groups.
Lung function among Swedish CF patients is good and annual rate of decline low, even in an
old cohort. The large proportion of adult patients emphasises future demands on CF care.
ª 2009 Published by Elsevier Ltd.Introduction
Patients with Cystic Fibrosis (CF) is an aging population.1 This
is the result of the development within many areas of the CF
care regimen and that patients are being referred to
centralised CF centre care as soon as possible. CF is a multi-
organ system disease that requires qualified care by a multi-
disciplinary team.2,3 In spite of this development, CF is still
a progressive, lethal disease. Reports show continuous
annual deterioration of lung function4,5 and progressive lung
disease accounts for more than 90% of the deaths in CF.6
CF is not yet screened for in Sweden. In 2002 the median
age of diagnosis was reported to be 9 months.1 A previous
study describes the frequency of DF508 among CF alleles in
Sweden to be 68%, 47% of the patients are homozygous and
41% heterozygous.7 The DF508 frequency in our population
is similar to that in other European countries, where the
DF508 frequency is reported to 51e88%.8 Centralised CF
care has been the situation in Sweden since the beginning
of the 1980s, and the care is organised into four CF centres
where 97% of all diagnosed CF patients are seen.1 Swedish
CF care follows the European standards of care for patients
with CF, which directs at all components of the disease.2
The cornerstones of treatment are active nutritional
support, aggressive antibiotic therapy, psycho-social
support and physiotherapy.2,3 The physiotherapy includes
inhalation therapy, airway clearance therapy (ACT) and
physical exercise.9 The ACT aim is described as to
compensate for the impaired mucociliary transport, and
a number of different techniques are nowadays available.9
One of the most often used techniques in the world,
especially among pre-school children is still the Postural
Drainage percussion and vibration.9 This technique has
not at all been used in Sweden since 1983, an effect of the
results from the long-term study by Andreasson et al.10
Instead, the airway clearance therapy based upon daily
physical exercise has replaced the Postural Drain-
age percussion and vibration, in all ages.11 This technique
is based upon immediate physiological effects from
moderate intense physical handling/activity/exercise on
lung volumes and respiratory patterns, in order to loosen
and mobilize secretions. The physical exercise is carried
out in conjunction with techniques for transporting and
evacuating mucus from the airways.10,11 The primary aim of
this treatment regimen is to avoid hypoxia by maintaining
all parts of the lungs aerated and possible to ventilate.
Recent discussions have emphasised the importance of
evaluating therapy in long-term studies (more than 1 year
observation period) where basic treatment is deemed to be
optimal. End-points or expected outcomes must be stable
lung function and physical status or a decrease in the rate
of decline of lung function.12
The aim of this study was to evaluate the CF care
package used since 25 years in Sweden.Material and methods
This study was based on longitudinal individual data that
were collected and prospectively evaluated to calculate
the lung function evolution during a 3-year period in the
whole Swedish CF population. The study was approved by
the local research ethics committees at the University
Hospitals in Go¨teborg, Lund, Stockholm and Uppsala. All
individuals with CF 7 years old who had performed an
annual expanded lung function control at least once
during the 3-year period at one of the four Swedish CF
centres during the study period were included. Informa-
tion was collected on Pancreatic insufficiency (PI), Body
Mass Index (BMI) and chronic Pseudomonas aeruginosa (Pa)
colonisation defined as positive sputum cultures on at
least two consecutive sputum samples within six months.
Chronic Pa colonisation is expressed as Paþ and not
chronically colonised as Pa. Patients who were lung or
heart/lung transplanted prior to the study start were
excluded.
Lung function data
Individual Forced Expiratory Volume in 1 s (FEV1) and Vital
Capacity (VC) were collected at the 1st and the 3rd year of
the study. The individual lung function data were collected
from the mandatory annual expanded lung function tests at
the Swedish CF centres. The annual expanded lung function
tests are always carried out with patients in a stable
condition, essentially at the same time of the year for each
individual. The lung function test technique is well known
to them since simple spirometries are carried out at each
out-patient clinic from early age and the annual expanded
tests have been carried out since the end of the 1970s. All
annual lung function measurements are always performed
in a body pletysmograph box by certified laboratory tech-
nicians, according to standardised procedures at each
centre’s accredited Department of Clinical Physiology. FEV1
and VC were used as end-points. FEV1 and VC are expressed
as percentage of predicted normal values (%p), obtained
from Solymar et al. for patients 7e17 years old and from
Quanjer et al. for patients 18 years old.13,14 For those
individuals who passed the age of 18 years during the study
period, the predicted values from Solymar et al were used
for the calculations at the end of the study. Stratification
was made due to chronic P. aeruginosa (Pa) colonisation
and basal FEV1%p.
Statistical analysis
Mean SD and median (range) FEV1%p and VC%p when
entering the study was summarised for the two age groups
7e17 (young) and 18 years old (adult), and selectively for
1078 U. Dennersten et al.the 30 year olds. Lung function was also summarised
separately for the Paþ and Pa groups.
Mean annual rate of change in FEV1%p and VC%p were
calculated for the two age groups. The mean annual rate of
change was calculated for the Paþ and Pa groups, divided
into <80% (subnormal) or 80% (maintained) FEV1%p when
entering the study. In some of the calculations, patients
30 years old were selected for additional analyses.
Continuous data are presented as mean values with
standard deviation and median values with range. Cat-
egorised variables are described using frequency table.
Linear mixed regression models were used for the assess-
ment of changes in lung function over time using subjects as
random variables and age, Pa status and FEV1%p above or
below 80% when entering the study as fixed variables when
applicable. The calculations were performed using the
mixed regression procedure in SAS (nr 8.2, SAS, Institute,
Cary, NC, www.sas.com/).
Results
At the start of the study, 371 individuals fulfilling the
inclusion criteria were defined. Data from two patients of
the 371 were not available at all, one due to multi-handicap
and the other due to his decision never to participate in the
expanded annual controls. Data was supplied only the 1st
year from 53 individuals (14%). Of these, four patients died
during the studied period (30, 30, 32 and 43 years old) and
six had lung transplantations (24, 27, 30, 33, 38 and 39
years old). The remaining 43 (12%) had not participated in
the expanded annual lung function test the 3rd year due to
unspecified reasons. During the studied period, data from
31 individuals were added. These individuals (age span 7e
50 years) were either <7 years old or not diagnosed when
the study started.
Baseline characteristics at the start of the study period
for the 369 individuals divided into the two different age




Pancreatic insufficient (PI), % 94
BMI, mean SD 18.8
Median (range) 18.6
Chronically colonised with Pseudomonas aeruginosa, % 35
FEV1, %predicted
Mean SD 90
Median (range) 92 (2
VC, %predicted
Mean SD 96
Median (range) 96 (3
FEV1/VC
Mean SD 0.93
Median (range) 0.96at inclusion was 40% within the adult group. The mean lung
function data for the 30 year olds alone was FEV1%p
65 28, median 63 (18e131) and mean VC%p was 89 23,
median 89 (37e140). Within the whole population studied
the proportion Paþ was 41%. The Pa group showed a mean
FEV1%p of 84 25, and the Paþ group 74 24.
The overall mean annual rate of decline of FEV1%p was
0.77% and 0.64% within <18 and 18 years olds, pZ 0.008,
respectively, pZ 0.0008. When analysing the 30 year olds
separately, the mean annual rate of decline of FEV1%p was
0.54%, pZ 0.08.
Fig. 1a and Table 2 demonstrates that the two young
groups with maintained FEV1%p at inclusion, either Paþ or
Pa and the Pa with low FEV1%p, proved to have a slow
annual rate of decline. Fig. 1b and Table 2 shows that the
adult group with maintained FEV1%p and Pa at inclusion
had a slightly slower annual rate of decline. Independently
of age, the two groups with subnormal FEV1%p and Paþ at
inclusion demonstrated the fastest annual rate of decline in
the study, pZ 0.04, respectively, pZ 0.0002 (Fig. 1a and
b, Table 2).
The annual rate of change of VC%p was slightly positive
for all the young subgroups (Fig. 2a and Table 3) and close
to zero for the two adult groups with maintained FEV1%p
either Paþ or Pa at inclusion (Fig. 2b and Table 3). For the
two adult groups with subnormal FEV1%p at inclusion, either
Paþ or Pa, the annual rate of decline of VC%p was
significant, pZ 0.045 and pZ 0.015, respectively (Fig. 2b
and Table 3). Mean annual rate of decline of VC%p for all
the 30 year olds alone was 0.45%, pZ 0.11.
Discussion
The aim of this study is to evaluate a 25-year-old CF care
package aiming at preventing lung function decline, not to
evaluate a rehabilitation intervention.
Data from almost the entire Swedish CF population 7
years old were collected. The study shows that lunghen divided due to age at the start of the 3-year study period
years old (nZ 176 (48%)) 18 years old (nZ 193 (52%))
49/51
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 0.13 0.76 0.17
(0.46e1.15) 0.79 (0.34e1.08)






























Figure 1 a) Evolution of FEV1%p in patients 7e17 years old without chronic Pseudomonas aeruginosa colonisation (Pa) and with
(Paþ), when divided into FEV1 80%p and <80%p at inclusion. PZ patients Pa and FEV1 80%p, OZ patients Paþ and
FEV1 80%p, BZ patients Pa and FEV1< 80%p, ,Z patients Paþ and FEV1< 80%p. (b) Evolution of FEV1%p in patients 18 years
old without chronic Pseudomonas aeruginosa colonisation (Pa) and with (Paþ), when divided into FEV1 80%p and <80%p at
inclusion. PZ patients Pa and FEV1 80%p, OZ patients Paþ and FEV1 80%p, BZ patients Pa and FEV1< 80%p, ,Z pa-
tients Paþ and FEV1< 80%p.
Aging cystic fibrosis patients and lung function 1079function as measured by FEV1%p in the Swedish CF population
is good compared to recently published reports.4,5,15e17
It is even more encouraging that the relative number of
females within the older group is unchanged and that the
big proportion 30 years old in our country-wide study also
shows a relatively well preserved lung function. Other
studies have shown mean rate of decline of FEV1%p from 1.1
to 3.9%.5,17e20 In contrast to the study of Konstan et al. in
2007 we found that patients with a maintained FEV1%p had
equal or reduced rate of decline than those with
a subnormal FEV1%p at inclusion.
5 The present study also
shows that the good VC%p at inclusion was well maintained
for the whole population and that the young cohort even
increased their VC%p slightly during the studied period,
which was unexpected.
CF lungs are reported morphologically normal at birth.21
But, studies have shown that even clinically asymptomatic
infants with CF have obstructed airways and air trapping
within the first months of life.21,22 This peripheral airway
obstruction decreases ventilation distribution gradually and
moreover poorly aerated, plugged and hypoxic areas of the
lungs may act as a source where micro-organisms such as Pa
survive and grow.23,24 The permanent bacterial growth and
prevailing inflammation further affects lung function andTable 2 Annual rate of change of the FEV1%p in the two age g
Subgroup 7e17 years Annual FEV1%p change with
Pa and FEV1 80%p 0.39%
Paþ and FEV1 80%p 0.46%
Pa and FEV1< 80%p 0.26%
Paþ and FEV1< 80%p 1.02%
Subgroup 18 years Annual FEV1%p change with
Pa and FEV1 80%p 0.30%
Paþ and FEV1 80%p 0.61%
Pa and FEV1< 80%p 0.55%
Paþ and FEV1< 80%p 0.90%ventilation distribution, resulting in an increasing propor-
tion of non-aerated and hypoxic parts of the lungs. Thereby
a vicious circle is started.
In hypoxic parts of the lungs, a commonly used Pa
antibiotic has shown to have a reduced efficacy due to the
anaerobic conditions.24 This may have been the reason for
the results in a study by Bosworth and Nielson, where
intravenous antibiotic courses when combined with inten-
sified airway clearance therapy gave better results than
when combined with only ‘‘routine’’ physiotherapy.25
Trying to maintain all parts of the lungs ventilated by the
help of ACT based upon physical exercise has constituted
one major aim of our physiotherapy regimen since the
beginning of the 1980:ies.
This study confirmed to a certain extent the findings
from other studies that Paþ patients show a faster decline
than the Pa.4,26e28 Our prevalence of Paþ turned out to
be low compared to similar populations.4,16 Our preventa-
tive ACT regimen aiming to maintain all parts of the lungs
ventilated could play a major role in postponing a rich
environment for growth of Pa.23,24,29 The lower prevalence
could partly explain the better outcome in Swedish CF
patients than in corresponding CF populations. Surprisingly,
our study showed that in patients with maintained FEV1%p,roups.
age 95%CI pZ
0.90 to þ0.13 0.1394
0.96 to þ0.05 0.0763
1.41 to þ0.89 0.6567
1.98 to 0.06 0.0378
age 95%CI pZ
0.66 to þ0.06 0.1007
1.04 to 0.19 0.0054
0.98 to 0.11 0.0136
1.36 to 0.44 0.0002


























Figure 2 (a) Evolution of VC%p in patients 7e17 years old without chronic Pseudomonas aeruginosa colonisation (Pa) and with
(Paþ), when divided into FEV1 80%p and <80%p at inclusion. PZ patients Pa and FEV1 80%p, OZ patients Paþ and
FEV1 80%p, BZ patients Pa and FEV1< 80%p, ,Z patients Paþ and FEV1< 80%p. (b) Evolution of VC%p in patients 18 years
old without chronic Pseudomonas aeruginosa colonisation (Pa) and with (Paþ), when divided into FEV1 80%p and <80%p at
inclusion. PZ patients Pa and FEV1 80%p, OZ patients Paþ and FEV1 80%p, BZ patients Pa and FEV1< 80%p, ,Z pa-
tients Paþ and FEV1< 80%p.
1080 U. Dennersten et al.Paþ does not necessarily influence the rate of decline,
which to our knowledge is not seen in any previous study.
However, we do not know for how long these patients have
been colonised, therefore, this study does not say whether
>3 years Paþ would affect the rate of decline or not.
Another factor brought up in discussions is the importance
of aging, which has been deemed to influence the FEV1%p
rate of decline for individuals with CF. But our study reports
that increasing age not necessarily is a confounding factor
influencing the rate of decline. A previous study based on
data in a national registry (Swedish Death Cause Registry),
showed low death rate due to CF in Sweden (0.9%) during
1991e1999 and median age at death 26 years.1 Bias due to
high mortality must be considered little during these years,
but an unknown survival selection from previous decades
must be considered.
It is well known that physical exercise causes immediate
physiological changes in breathing pattern, lung volumes
and ventilation distribution in obstructed airways.30e32 The
degree of changes is dependent on the severity of airway
obstruction, and is different to changes in healthy individ-
uals. Especially the increased End Expiratory Lung Volume
(EELV) and the reduced Trapped Air Index (TAI) may be of
interest when discussing aerating hypoxic parts of the lungs
and getting air behind sputum clogs and plugs, preparatoryTable 3 Annual rate of change of the VC%p in the two age gro
Subgroup 7e17 years Annual VC%p change with
Pa and FEV1 80%p þ0.12%
Paþ and FEV1 80%p þ0.22%
Pa and FEV1< 80%p þ0.28%
Paþ and FEV1< 80%p þ0.68%
Subgroup 18 years Annual VC%p change with
Pa and FEV1 80%p þ0.01%
Paþ and FEV1 80%p 0.02%
Pa and FEV1< 80%p 0.45%
Paþ and FEV1< 80%p 0.57%and in conjunction with ACT. Added to that, a decreased re-
absorption of Naþ from airway epithelia during physical
exercise in CF has been described.33 This may improve the
sol phase defect of the airway surface liquid, which may
help to loosen secretions from the mucosa. Patients report
and studies have shown increased mucus expectoration
after physical exercise.34e37 In our physiotherapy regimen,
respiratory physiological effects of moderate intensive
physical exercise are utilized as the airway clearance
therapy in conjunction with assisted autogenic drainage
(AAD) in all infants and toddlers, with autogenic drainage
(AD) or forced expiration technique (FET) and directed
coughing for children, adolescents and adults.9e11 This
combination is replacing, not added to Postural Drain-
age percussion and vibration which is still the most
commonly used technique for infants, toddlers and pre-
school children in a global perspective. Alternative airway
clearance techniques may be used in the more severely ill,
as well as in adolescents and adults, whereas physical
exercise always is added to the airway clearance therapy.9
Physical exercise programmes are not specific or stand-
ardised in the Swedish physiotherapy approach. However,
there is a standardised principle that the physical exercise
programmes are tailored to the capacity and interest of each
individual. The programmes are build upon agreements withups.
age 95%CI pZ
0.36 to þ0.60 0.6309
0.26 to þ0.69 0.3736
0.70 to þ1.26 0.5749
0.49 to þ1.86 0.2520
age 95%CI pZ
0.29 to þ0.31 0.9666
0.38 to þ0.33 0.8937
0.88 to 0.01 0.0455
1.02 to 0.11 0.0147
Aging cystic fibrosis patients and lung function 1081the patients and involve (1) physiological cardio-respiratory
aims and immediate consequences on the respiratory
pattern and ventilation distribution, (2) musculoskeletal
aims (posture, chest and chest wall mobility, muscle
strengthening exercises and bone mass density). The pro-
grammes are frequently up-dated. With the help of this
regimen included in the treatment package from the very
beginning, all these aims can be achieved at the same time
as the ACT, which makes the daily treatment more stimu-
lating and time efficient for patients and families. This 25
years old regimen may have contributed to the good lung
function and low rate of decline presented in this study.
There are limitations of the design in this study. The
most important is the absence of a control group. This study
is not an intervention study, but an evaluation of 25 years of
CF care where the biggest difference from international
guidelines is the physiotherapy approach. Analyses and
interpretation of the results has to rely on historical data
and similar populations. Without a control group it is diffi-
cult to establish the exact role of our physiotherapy
regimen. One previous randomised controlled study noticed
a more slow decline in lung function in the exercise group
than in the control group.38 Our study is based on results
from already performed annual expanded standardised lung
function tests during a 3-year interval, which does not allow
bias. With the help of statistical analysis the study evalu-
ates 25 years of clinical work in the Swedish CF centres. We
regard the low proportion of missing data of minor impor-
tance compared to the obvious advantage of this country-
wide study containing data from almost all known Swedish
CF patients, which avoids bias. Previous studies seldom
report data from a total CF population.15,16 The spirometry
data for the 43 patients (median age 26 years 11e58) who
did not provide data at the end of the study due to
unspecified reasons showed similar lung function (VC 84%p
and FEV1 70%p) collected at corresponding time for the
expanded annual control. However, these lung function
tests were obtained in the non-accredited out-patient
clinic and were, therefore, not included in the study.Conclusion
Lung function among Swedish CF patients is well preserved
in all ages. Mean annual rate of FEV1%p decline was low.
Chronic Pa colonisation among the 7e17 years old with
maintained lung function did not signify an increased rate
of decline. VC%p improved slightly during the studied
period within the young group. The airway clearance
therapy approach based on moderate intense daily physical
exercise may have contributed to the good results. This
approach has even replaced the Postural Drainage 
Percussion and Vibration among infants and toddlers since
early 1980s. However, this long-term evaluation was carried
out without a control group, which makes it difficult to
establish the exact role of physical exercise. Future long-
term studies about the role of physical exercise in relation
to lung function development are of interest. This country-
wide population shows a high proportion of patients 30
years old, which gives novel data about the aging CF
patients emphasising demands of great importance for
future adult CF care.Conflict of interest
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